Oxybutynin, a common drug to manage overactive bladder, may help alleviate hot flash symptoms among men receiving androgen deprivation therapy for prostate cancer.

Telix Pharmaceuticals updates on its prostate cancer Phase 3 trial, dosing the first Part 2 patient and outlining regulatory plans. Telix Pharmaceuticals has dosed the first patient in Part 2 of its ...

A key outcome from lung cancer screening studies is the concept of ‘stage-shift’ seen in screen-detected cancers compared ...

When Andy Provencher crashed his mountain bike and tumbled over the handlebars, he thought his wife's reaction would be his biggest problem. It was June 2020, when COVID-19 was soaring nationwide. The ...